



# Department of Health & Social Care

Freedom of Information Team  
Department of Health and Social Care  
39 Victoria Street  
London SW1H 0EU

[www.gov.uk/dhsc](http://www.gov.uk/dhsc)

Ms Louise Bicknell

By email to: [request-879342-bfe57a02@whatdotheyknow.com](mailto:request-879342-bfe57a02@whatdotheyknow.com)

18 October 2022

Dear Ms Bicknell,

## Freedom of Information Request Reference FOI-1415521

Thank you for your request dated 16 August to the Department of Health and Social Care (DHSC), a copy of which can be found in the accompanying annex.

We understand that your new request is a follow up to FOI-1412406 received on 18 July to which we responded to on 27 July under section 1(3) (clarification) and FOI-1414071 received on 1 August, to which we responded to on 12 August also under section 1(3) (clarification).

Your request has been handled under the Freedom of Information Act 2000 (FOIA) and we apologise for the long delay in replying.

**Recommendations on (policy or otherwise) and be involved in the process of a COVID treatments journey through the NHS review process, including those who receive the final papers and make the decision whether to go ahead and purchase it for the NHS.**

DHSC holds information relevant to your request.

However, as the information held by DHSC is in the public domain we will, under section 21 of the FOIA (information accessible to the applicant by other means), refer you to the published source.

The key group that considered the clinical evidence relating to whether Evusheld should be procured through emergency routes at this time was the Research to Access Pathway for Investigational Drugs for COVID-19 (RAPID C-19) [Research to access pathway for investigational drugs for COVID-19 \(RAPID C-19\) | NICE](#). RAPID C-19 is a multi-agency initiative set up in response to the pandemic which aims to get treatments for COVID-19 to NHS patients quickly and safely. Please see the [RAPID C-19 Oversight Group report: review of Evusheld - GOV.UK \(www.gov.uk\)](#) for information regarding the evidence considered in relation to Evusheld.

**Dates for all meetings of this taskforce from 1 October 2021 onwards, including future scheduled meetings.**

DHSC holds information relevant to your request.

Captured below are the dates on which the ATF Programme Board, TTF, ATF Operations Board, TTF Operations Board, ATTF Programme Board and ATTF Strategy Board met. Your request also asks for the board meetings held by the Antivirals Taskforce (ATF) board and Therapeutics Taskforce Programme Board (TTF). Whilst they were not involved in the decision to not procure Evusheld at this time, the information you have requested is set out below.

**ATF Programme Board (operational until April 2022) meeting dates:**

- 8<sup>th</sup> October 2021
- 22<sup>nd</sup> October 2021
- 5<sup>th</sup> November 2021
- 19<sup>th</sup> November 2021
- 3<sup>rd</sup> December 2021
- 17<sup>th</sup> December 2021
- 14<sup>th</sup> January 2022
- 28<sup>th</sup> January 2022
- 11<sup>th</sup> February 2022
- 25<sup>th</sup> February 2022
- 11<sup>th</sup> March 2022
- 25<sup>th</sup> March 2022

**TTF Programme Board (operational until April 2022) meeting dates:**

- 15<sup>th</sup> August 2021
- 12<sup>th</sup> November 2021
- 10<sup>th</sup> December 2021
- 21<sup>st</sup> January 2022
- 18<sup>th</sup> February 2022
- 18<sup>th</sup> March 2022

**ATTF Programme Board (operational from April 2022) meeting dates:**

- 7<sup>th</sup> April 2022
- 5<sup>th</sup> May 2022
- 9<sup>th</sup> June 2022
- 28<sup>th</sup> July 2022

**Future Scheduled ATTF Programme Board meeting dates:**

- 25<sup>th</sup> August 2022
- 22<sup>nd</sup> September 2022
- 20<sup>th</sup> October 2022
- 17<sup>th</sup> November 2022
- 15<sup>th</sup> December 2022
- 12<sup>th</sup> January 2023
- 9<sup>th</sup> February 2023
- 9<sup>th</sup> March 2023

**ATF Operations Board meeting dates:**

- 30th June 2021
- 26th July 2021
- 27th August 2021
- 6th October 2021
- 11th November 2021
- 9th December 2021
- 13th January 2022
- 10th February 2022
- 9th March 2022
- 30th March 2022

**TTF Operations Board meeting dates:**

- 5th May 2021
- 14th June 2021
- 15th December 2021
- 3rd February 2022

**ATTF Strategy Board (replaced Operations Board when the ATF and TTF merged in April 2022) meeting dates:**

- 27th April 2022
- 18th May 2022
- 16th June 2022
- 13th July 2022

**Future scheduled ATTF Strategy Board meeting dates:**

- 20<sup>th</sup> September 2022
- 18<sup>th</sup> October 2022
- 15<sup>th</sup> November 2022
- 13<sup>th</sup> December 2022
- 10<sup>th</sup> January 2023
- 7<sup>th</sup> February 2023
- 7<sup>th</sup> March 2023

**Details of the membership of this taskforce from 1 October 2021 onwards, detailing who has left/been replaced and by whom. Their roles and functions.**

DHSC holds information relevant to your request. Please note that some of this information has been redacted under section 40(2) of the FOIA, which provides for the protection of personal information. Section 40 prohibits a public body from disclosing personally identifiable information, as doing so would contravene data protection principles.

The 'Taskforce' refers to the name of the DHSC Antivirals and Therapeutics policy team (roughly 70 Civil Servants), as opposed to being the actual decision-making body.

Captured below is the membership structure of the Taskforce's decision-making governance boards- the Programme Board and the Operations Board.

**ATF Programme Board Membership (October 2021- March 2022)**

<b>Name</b>	<b>Representing</b>	<b>Role</b>
Charlotte Taylor (Chair)	Antivirals Taskforce	Antivirals Taskforce SRO
Julie Alexander	Vaccine Deployment Team	Deputy Director for vaccines deployment
Name withheld under s40 –	HMT	Global Issues Team, Vaccines and Therapeutics in HMT
Name withheld under s40 –	Cabinet Office	Vaccines & Therapeutics Team, Covid-19 Taskforce in the Cabinet Office
Mike Batley	SRE	Deputy Director, NIHR funding and research
Name withheld under s40 –	Commercial	Senior manager, Vaccines and Medical Countermeasures Team
Name withheld under s40 –	VTF	VTF Strategy team lead
David Hayward	Antivirals Taskforce	ATF Deputy Director
Alex Churchill	Antivirals Taskforce	ATF Deputy Director,
Nichola Pitt	Antivirals Taskforce	ATF Deputy Director
Fionn Craig	Antivirals Taskforce	ATF Deputy Director
Name withheld under s40 –	Antivirals Taskforce	Head of PMO
David Penhallurick	DHSC, Central Finance	Central Finance

**TTF Programme Board Membership (October 2021- March 2022)**

<b>Name</b>	<b>Representing</b>	<b>Role</b>
Charlotte Taylor (Chair)	Therapeutics Taskforce	Therapeutics Taskforce SRO
Gail Miflin	NHSBT	Head of Project delivery for convalescent plasma collection
Nick Lemoine	NIHR	Medical Director NIHR

Kathryn Glover/ Helen Lovell	DHSC Medicines Supply Team	Director or Deputy Director
Mike Batley	SRE	Deputy Director, NIHR funding and research
Daniel O'Conner	MHRA	Regulatory Issues
Carla Deakin	NICE	Programme Director
Patrick Chinnery	UKRI	UKCTAP Chair
David Hayward	Therapeutics Taskforce	TTF Deputy Director
Alex Churchill	Therapeutics Taskforce	TTF Deputy Director
Nichola Pitt	Therapeutics Taskforce	TTF Deputy Director
Ian King	Therapeutics Taskforce	TTF Deputy Director
Fionn Craig	Therapeutics Taskforce	TTF Deputy Director
Name withheld under s40 –	Therapeutics Taskforce	Head of PMO
David Penhallurick	Therapeutics Taskforce	Central Finance

#### **ATTF Programme Board Membership (April 2022 onwards)**

<b>Name</b>	<b>Representing</b>	<b>Role</b>
Charlotte Taylor (Chair)	Antivirals and Therapeutics Taskforce	Antivirals and Therapeutics Taskforce SRO
Gareth Arthur	NHSE/I	Director - NHS England & NHS Improvement
Name withheld under s40 –	HM Treasury	Spending Principal for Covid Vaccines and Therapeutics
Mike Batley	DHSC, SRE	Deputy Director - NIHR funding and research
Name withheld under s40 –	UKHSA	UKHSA testing policy team
Name withheld under s40 –	UKHSA	UKHSA testing policy team
Lucy Mason	DHSC	Deputy Director - DHSC Commercial
Name withheld under s40 –	NHSE/I	Operations Lead – Primary Care Covid Response
Alison Ward	NHSD	Programme Director

Peter Appleton	DHSC, Central Finance	Deputy Director - Central Finance
Carla Deakin	NICE	Programme Director - Commercial and Managed Access
Helen Gibson	DHSC	Deputy Director - Medicine Supply
David Hayward	Antivirals and Therapeutics Taskforce	ATTF Deputy Director
Alex Churchill	Antivirals and Therapeutics Taskforce	ATTF Deputy Director
Fionn Craig	Antivirals and Therapeutics Taskforce	ATTF Deputy Director
Reene Deba (from May 2022)	Antivirals and Therapeutics Taskforce	ATTF Deputy Director
Name withheld under s40 –	Antivirals and Therapeutics Taskforce	Head of PMO

#### **ATF Operations Board membership (October 2021- March 2022):**

<b>Name</b>	<b>Representing</b>	<b>Role</b>
Clara Swinson (Member from July 2021 –March 2022; Chair from November 2021 – March 2022)	DHSC	Director General Global Health Group, DHSC
Eddie Gray	Antivirals Taskforce	Chair of the Antivirals Taskforce
Charlotte Taylor	Antivirals Taskforce	Director of the Antivirals Taskforce
Jonathan Van-Tam (Member from June 2021- February 2022)	DHSC	DHSC Deputy Chief Medical Officer
Louise Wood	DHSC, SRE (Science, Research and Evidence) Directorate	SRE Director
Andy Brittan	DHSC, Central Finance	DHSC Director General, Finance
June Raine	MHRA	Chief Executive of the MHRA
Simon Whitfield	Government Office for Science (GO-Science)	GO-Science, Director
Stephen Powis	NHSE	National Medical Director, NHSE
Rosalind Campion	Office for Life Sciences (OLS)	OLS Director
Lucy Mason	DHSC Commercial	DHSC Commercial Director
Doug Gurr	DHSC	Non-Executive Director, DHSC
Helen Dickinson	Cabinet Office	Cabinet Office Director

Kate Smith	Cabinet Office	Cabinet Office Director
Nick Lemoine	NIHR	Medical Director, NIHR
Ed Scully	DHSC	Director, Primary Care, DHSC
Lucy Chappell	DHSC	DHSC, Chief Scientific Advisor
Gareth Arthur	NHSE	SRO for Antiviral Deployment, NHSE
Kiren Collison	NHSE	Deputy Medical Director for Primary Care
Susan Hopkins	UKHSA	Chief Medical Advisor, UKHSA
Joe Randall	HM Treasury	Vaccines and Therapeutics Deputy Director, HM Treasury
Nikki Pitt	DHSC	ATF Deputy Director
Ian King (member from June 2021- January 2022)	DHSC	ATF Deputy Director
Alex Churchill	DHSC	ATF Deputy Director
David Hayward	DHSC	ATF Deputy Director
Fionn Craig	DHSC	ATF Deputy Director
Steve Oldfield (member from October 2021- December 2021)	DHSC	DHSC Chief Commercial Officer
Keith Ridge (member from July 2021- December 2021)	NHSE	Chief Pharmacist, NHSE
Kristen McLeod (member from June 2021- November 2021)	OLS	OLS Director
Jamie Turner (member from June 2021- February 2022)	NHS Test and Trace	NHS Test and Trace Director

### **TTF Operations Board Membership (October 2021- March 2022)**

<b>Name</b>	<b>Representing</b>	<b>Role</b>
Clara Swinson (Member from July 2021 –March 2022; Chair from November 2021 – March 2022)	DHSC	Director General Global Health Group, DHSC
Charlotte Taylor	Antivirals Taskforce	Director of the Antivirals Taskforce
Jonathan Van-Tam (Member from June 2021- February 2022)	DHSC	DHSC Deputy Chief Medical Officer

Jamie Turner	NHS Test and Trace	Test and Trace Director
Andy Brittan	DHSC, Central Finance	DHSC Director General, Finance
June Raine	MHRA	Chief Executive of the MHRA
Stephen Powis	NHSE	National Medical Director, NHSE
Lucy Mason	DHSC Commercial	DHSC Commercial Director
Kate Smith	Cabinet Office	Cabinet Office Director
Nick Lemoine	NIHR	Medical Director, NIHR
Joe Randall	HM Treasury	Vaccines and Therapeutics Deputy Director, HM Treasury
Nikki Pitt	DHSC	TTF Deputy Director
Ian King (member from June 2021- January 2022)	DHSC	TTF Deputy Director
Alex Churchill	DHSC	TTF Deputy Director
David Hayward	DHSC	TTF Deputy Director
Fionn Craig	DHSC	TTF Deputy Director
Steve Oldfield (member from October 2021- December 2021)	DHSC	DHSC Chief Commercial Officer
Mary Jones	OLS	OLS Deputy Director
Antonia Williams	DHSC Vaccines Deployment	COVID-19 Vaccines Deployment Director

### **TTF Strategy Board Membership (April 2022 onwards)**

<b>Name</b>	<b>Representing</b>	<b>Role</b>
Clara Swinson (Chair from April 2022)	DHSC	Director General Global Health Group, DHSC
Charlotte Taylor	Antivirals Taskforce	Director of the Antivirals Taskforce
Thomas Waite	DHSC	DHSC Deputy Chief Medical Officer
Elizabeth Woodeson	Medicines and Pharmacy Directorate, DHSC	Director of Medicines and Pharmacy, DHSC
Louise Wood (member from April 2022- June 2022)	DHSC, SRE (Science, Research and Evidence) Directorate	SRE Director
Andy Brittan	DHSC, Central Finance	DHSC Director General, Finance
June Raine	MHRA	Chief Executive of the MHRA
Simon Whitfield	Government Office for Science (GO-Science)	GO-Science, Director



Stephen Powis	NHSE	National Medical Director, NHSE
Rosalind Campion	Office for Life Sciences (OLS)	OLS Director
Lucy Mason	DHSC Commercial	DHSC Commercial Director
Doug Gurr	DHSC	Non-Executive Director, DHSC
Helen Dickinson	Cabinet Office	Cabinet Office Director
Kate Smith	Cabinet Office	Cabinet Office Director
Nick Lemoine	NIHR	Medical Director, NIHR
Ed Scully	DHSC	Director, Primary Care, DHSC
Lucy Chappell	DHSC	DHSC, Chief Scientific Advisor
Gareth Arthur	NHSE	SRO for Antiviral Deployment, NHSE
Kiren Collison	NHSE	Deputy Medical Director for Primary Care
Susan Hopkins	UKHSA	Chief Medical Advisor, UKHSA
Joe Randall	HM Treasury	Vaccines and Therapeutics Deputy Director, HM Treasury
Alex Churchill	DHSC	ATTF Deputy Director
David Hayward	DHSC	ATTF Deputy Director
Reene Deba	DHSC	ATTF Deputy Director
Fionn Craig	DHSC	ATTF Deputy Director
Steve Oldfield (member from October 2021- December 2021)	DHSC	DHSC Chief Commercial Officer
Keith Ridge (member from July 2021- December 2021)	NHSE	Chief Pharmacist, NHSE
Kristen McLeod (member from June 2021- November 2021)	OLS	OLS Director
Alex Holmes	Cabinet Office	Deputy Director, Cabinet Office
Manuela Solera-Deuchar	DHSC Finance	Finance Director, DHSC
Hannah Taylor	UKHSA	Director, UKHSA
Paul MacNaught	Vaccine Deployment, DHSC	COVID-19 Vaccine Deployment, DHSC
Gareth Rhys Williams	Cabinet Office	Director General, Cabinet Office Commercial
Maeve Conolly (member from April 2022- July 2022)	HM Treasury	Deputy Director, HM Treasury
Rob Mantanari (member from July 2022- present)	HM Treasury	Deputy Director, HM Treasury

Melinda Johnson	DHSC	Commercial Director, DHSC
Heidi Granger	Vaccines Taskforce	Deputy Director, Vaccines Taskforce
Meera Chand	UKHSA	Director, UKHSA

**A structure chart setting out the bodies involved in the COVID 19 medical approval process from 1 October 2021 onwards.**

DHSC holds the information you have requested.

However, as the information held by the Department is in the public domain we will, under Section 21 of the FOIA (information accessible to the applicant by other means), refer you to the published source.

<https://www.nice.org.uk/Media/Default/About/what-we-do/covid-19/RAPID-C19-oversight-group-membership.docx>,

[RAPID-C19-interim-process-guide.docx \(live.com\)](#). Please see, Annex 1 for the process chart.

If you are not satisfied with the handling of your request, you have the right to appeal by asking for an internal review. This should be sent to [freedomofinformation@dhsc.gov.uk](mailto:freedomofinformation@dhsc.gov.uk) or to the address at the top of this letter and be submitted within two months of the date of this letter.

Please remember to quote the reference number above in any future communication.

If you are not content with the outcome of your internal review, you may complain directly to the Information Commissioner's Office (ICO). Generally, the ICO cannot make a decision unless you have already appealed our original response and received our internal review decision. You should raise your concerns with the ICO within three months of your last meaningful contact with us.

Guidance on contacting the ICO can be found at <https://ico.org.uk/global/contact-us> and information about making a complaint can be found at <https://ico.org.uk/make-a-complaint>.

Yours sincerely,

Freedom of Information Team  
[freedomofinformation@dhsc.gov.uk](mailto:freedomofinformation@dhsc.gov.uk)

## **Annex**

Dear Department of Health and Social Care,

Thank you for your clarification request

In respect of a structure chart I would expect to see the bodies/committees/policy teams/units/task forces etc that would contribute to, make recommendations on (policy or otherwise), and be involved in the process of a COVID treatments journey through the NHS review process, including those who receive the final papers and make the decision whether to go ahead and purchase it for the NHS. I would also expect to see the details of which body provides the secretarial support (agenda preparation, minutes etc) for each stage of the process.

Therefore I would expect there to be a flow diagram with a written explanatory process. I anticipate that things have changed over time, hence the enquiry from 1 October 2021 to date catering for changes.

Surely this is a documented governance flow chart and documented explanation exists as it would be expected as a base standard in any regulated industry body?

I have had to make such a broad inquiry in respect of the bodies involved as there are so many different bodies' names on your website and in parliamentary answers

For the avoidance of doubt when I refer to Evusheld this is the brand name of tixagevimab and cilgavimab or what other name you have used for these compounds individually or collectively for the purposes of your processes.

I look forward to receiving an answer on this

Yours faithfully,

Louise Bicknell